Information Provided By: 
Fly News Breaks for May 10, 2018
ADAP
May 10, 2018 | 08:58 EDT
SunTrust analyst Peter Lawson raised his price target on Adaptimmune to $18 and kept his Buy rating after its Q1 results. The analyst attributes his target price increase to the company's "safety review committee recommending moving to the 1BN cell dose for the MAGE-A10 program". Lawson is also basing his model on the MAGE-10 and A4 efficacy in the second half of this year, along with further NY-ESO data readout at ASCO.
News For ADAP From the Last 2 Days
There are no results for your query ADAP
